Notably, YTHDF1 exhibits high expression levels in colorectal adenocarcinoma, lung adenocarcinoma (LUAD) and colorectal adenocarcinoma tissues, while YTHDF2 is notably up‐regulated in breast cancer (BRCA), head and neck squamous cell carcinoma (HNSC), LUAD and prostate cancer (PRAD). Here, YTHDF2 is linked to prostate carcinoma.